Remedent (REMI) 10-K 29 Jun 20 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2020	Jun. 29, 2020	Dec. 31, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	REMEDENT, INC.
Entity Central Index Key	0001078037
Trading Symbol	REMI
Document Type	10-K
Document Period End Date	Mar. 31, 2020
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Amendment Flag	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		19,995,969
Entity Public Float			$ 3,599,274

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2020	Mar. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 114,634	$ 66,539
Accounts receivable, net of allowance for doubtful accounts of $154,447 at March 31, 2020 and $157,903 at March 31, 2019	329,340	233,908
Inventories, net	90,841	110,962
Prepaid expense	146,249	244,524
Total current assets	681,064	655,933
PROPERTY AND EQUIPMENT, NET	67,092	125,733
OTHER ASSETS
Equity investment in GlamSmile Asia Ltd (Note 3)	2,150,724	2,306,817
Investment in Condor Technology (Note 3)	1,159,561	1,335,680
Equity investment in Metrics in Balance (Note 3)	3,450,598	3,472,011
Total assets	7,509,039	7,896,174
CURRENT LIABILITIES:
Accounts payable	2,294,884	1,919,095
Accrued liabilities	486,763	450,347
Deferred revenue	100,571	63,852
Total current liabilities	2,882,218	2,433,294
Long-term debt	5,455
TOTAL LIABILITIES:	2,887,673	2,433,294
EQUITY:
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)	0	0
Common stock, $0.001 par value; (50,000,000 shares authorized, 19,995,969 shares issued and outstanding at March 31, 2020 and March 31, 2019 respectively)	19,996	19,996
Treasury stock, at cost; 723,000 shares outstanding at March 31, 2020 and March 31, 2019 respectively	(831,450)	(831,450)
Additional paid-in capital	24,906,269	24,906,269
Accumulated deficit	(18,575,388)	(17,717,166)
Accumulated other comprehensive income (loss)	(1,070,239)	(1,082,992)
Obligation to issue shares (Note 3)	97,500	97,500
Total Remedent, Inc. stockholders' equity	4,546,688	5,392,157
Non-controlling interest	74,678	70,723
Total stockholders' equity	4,621,366	5,462,880
Total liabilities and equity	$ 7,509,039	$ 7,896,174

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
CONSOLIDATED BALANCE SHEETS
Allowance for doubtful accounts	$ 154,447	$ 157,903
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	50,000,000	50,000,000
Common Stock, shares issued	19,995,969	19,995,969
Common Stock, shares outstanding	19,995,969	19,995,969
Treasury stock, shares	723,000	723,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CONSOLIDATED STATEMENTS OF OPERATIONS
Net sales	$ 1,064,419	$ 1,603,741
Cost of sales	322,248	486,495
Gross profit	742,171	1,117,246
Operating Expenses
Research and development		120
Sales and marketing	401,669	727,897
General and administrative	748,858	1,008,806
Depreciation and amortization	71,251	97,770
TOTAL OPERATING EXPENSES	1,221,778	1,834,593
OPERATING INCOME (LOSS)	(479,607)	(717,347)
NON-OPERATING INCOME (EXPENSE)
Equity (loss) income from investments (Note 3)	(353,625)	2,851,529
Interest expense	(14,086)	(10,643)
Other (expense)	(4,620)	(3,542)
TOTAL OTHER INCOME	(372,331)	2,837,344
(LOSS) PROFIT FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(851,938)	2,119,997
Income tax (expense) recovery	(2,329)	(874)
NET (LOSS) INCOME BEFORE NON-CONTROLLING INTEREST, NET OF TAX	(854,267)	2,119,123
NET LOSS (INCOME) ATTRIBUTABLE TO NON-CONTROLLING INTEREST	3,955	(9,673)
NET INCOME (LOSS) ATTRIBUTABLE TO REMEDENT INC. COMMON SHAREHOLDERS	$ (858,222)	$ 2,128,796
(LOSS) PROFIT PER SHARE
Basic	$ (0.040)	$ 0.11
Fully diluted	$ (0.04)	$ 0.11
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic	19,995,969	19,995,969
Fully diluted	19,995,969	19,995,969

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net (loss) income	$ (854,267)	$ 2,119,123
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:
Foreign currency translation adjustments	12,753	31,922
TOTAL COMPREHENSIVE (LOSS) INCOME	(841,514)	2,151,045
LESS: COMPREHENSIVE (INCOME) LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS	3,955	(9,673)
COMPREHENSIVE PROFIT ATTRIBUTABLE TO REMEDENT, INC. common shareholders	$ (845,469)	$ 2,160,718

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Obligation to Issue Shares [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Other Comprehensive Income (Loss) [Member]	Parent [Member]	Non-controlling Interest [Member]	Total
Balance at Mar. 31, 2018	$ 19,996	$ 24,906,269	$ 97,500	$ (20,024,323)	$ (831,450)	$ (936,553)	$ 3,231,439	$ 80,396	$ 3,311,835
Balance (in shares) at Mar. 31, 2018	19,995,969
ASU 2016-01 Transition Adjustment	$ 0	0	0	178,361	0	(178,361)	0	0	0
Other comprehensive income	0	0	0	0	0	31,922	31,922	0	31,922
Net income (loss) for the year	0	0	0	2,128,796	0	0	2,128,796	(9,673)	2,119,123
Balance at Mar. 31, 2019	$ 19,996	24,906,269	97,500	(17,717,166)	(831,450)	(1,082,992)	5,392,157	70,723	5,462,880
Balance (in shares) at Mar. 31, 2019	19,995,969
Other comprehensive income	$ 0	0	0	0	0	12,753	12,753	0	12,753
Net income (loss) for the year	0	0	0	(858,222)	0	0	(858,222)	3,955	(854,267)
Balance at Mar. 31, 2020	$ 19,996	$ 24,906,269	$ 97,500	$ (18,575,388)	$ (831,450)	$ (1,070,239)	$ 4,546,688	$ 74,678	$ 4,621,366
Balance (in shares) at Mar. 31, 2020	19,995,969

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss) for the year	$ (854,267)	$ 2,119,123
Adjustments to reconcile net profit to net cash used by operating activities:
Depreciation and amortization	71,251	97,770
Inventory reserve	(24,329)	(61,112)
Allowance for doubtful accounts	(3,456)	(32,023)
Investment loss (income)	353,625	(2,851,529)
Changes in operating assets and liabilities:
Accounts receivable	(95,432)	923,516
Inventories	20,121	12,150
Prepaid expenses	255,413	52,687
Accounts payable	375,791	350,030
Accrued liabilities	(33,888)	26,808
Deferred revenue	36,719	(18,024)
Due to related parties		(51,778)
Net cash provided by operating activities	101,548	567,618
NET INCREASE IN CASH	101,548	567,618
Effect of exchange rate changes on cash and cash equivalents	(53,453)	(593,954)
CASH AND CASH EQUIVALENTS, BEGINNING	66,539	92,875
CASH AND CASH EQUIVALENTS, ENDING	114,634	66,539
Supplemental Cash Flow Information :
Interest paid	14,086	10,643
Income taxes paid	$ 0	$ 0

DESCRIPTION OF THE COMPANY AND

DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION	12 Months Ended
	Mar. 31, 2020
DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION
DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION	1. DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION The Company is a manufacturer and distributor of cosmetic dentistry products, including a full line of professional dental tooth whitening products which are distributed in Europe, Asia and the United States. The Company manufactures many of its products in its facility in Ghent, Belgium as well as outsourced manufacturing in Beijing, China. The Company distributes its products using both its own internal sales force and through the use of third party distributors. In these notes, the terms “Remedent”, “Company”, “we”, “us” or “our” mean Remedent, Inc. and all of its subsidiaries, whose operations are included in these consolidated financial statements. The Company’s financial statements have been prepared on an accrual basis of accounting, in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein. These financial statements of the Company are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Despite the net profit for the accounting years ending March 31, 2019, March 31, 2018 and March 31, 2017, the accumulated losses of the March 31, 2020 year end and past years affect the financial situation of the Company. The continuation of the Company as a going concern is dependent upon the Company’s ability to continue to generate profitable operations. As of March 31, 2020 the Company had a working capital deficit of $2,201,154 and an accumulated deficit of $18,575,388. Additional funding may be required in order to support the Company’s operations and the execution of its business plan. There can be no assurance that the Company will be successful in raising the required capital or that it will ultimately attain a successful level of operations. These risks, among others, are also discussed in ITEM 1A – Risk Factors. The Company has conducted a subsequent events review through the date the financial statements were issued, and has concluded that there were no subsequent events requiring adjustments or additional disclosures to the Company’s financial statements at March 31, 2020.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization and Principles of Consolidation The accompanying consolidated financial statements include the accounts of: Remedent N.V. (incorporated in Belgium) located in Ghent, Belgium, Remedent Professional, Inc. and Remedent Professional Holdings, Inc. (both incorporated in California and inactive), Glamtech-USA, Inc. (a Delaware corporation acquired effective August 24, 2008), Condor North America LLC, a Nevada corporation, Remedent N.V.’s 50% owned subsidiary, Biotech Dental Benelux N.V., a Belgium private company located in Ghent, Remedent N.V.’s 51% owned subsidiary, GlamSmile Deutschland GmbH, a German private company located in Munich (effective March 31, 2014 this subsidiary is inactive), Remedent N.V.’s 80% owned subsidiary, GlamSmile Rome, an Italian private company located in Rome (effective March 31, 2014 this subsidiary is inactive) Remedent N.V. owns 21.51 % of Glamsmile Dental Technology Ltd., a Cayman Islands company (“Glamsmile Dental”). The subsidiaries of Glamsmile Dental include: Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong, Beijing Glamsmile Technology Development Ltd., a 100% owned subsidiary or GlamSmile Asia, its 80% owned subsidiary Beijing Glamsmile Trading Co., Ltd. and its 98% owned subsidiary Beijing Glamsmile Dental Clinic Co., Ltd., including its 100% owned Shanghai Glamsmile Dental Clinic Co., Ltd., its 100% owned Guangzhou Dental Clinic Co., Ltd. and its 50% owned Whenzhou GlamSmile Dental Clinic Ltd., which are accounted for using the equity method after January 31, 2012 (see Note 3 – Long-term Investment) Remedent, Inc. is a holding company with headquarters in Ghent, Belgium. Remedent Professional, Inc. and Remedent Professional Holdings, Inc. have been dormant since inception. For all periods presented, all significant inter-company accounts and transactions have been eliminated in the consolidated financial statements and corporate administrative costs are not allocated to subsidiaries. Pervasiveness of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, the Company evaluates estimates and judgments, including those related to revenue, bad debts, inventories, fixed assets, intangible assets, stock based compensation, income taxes, and contingencies. Estimates are based on historical experience and on various other assumptions that the Company believes reasonable in the circumstances. The results form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Revenue Recognition The Company recognizes revenue from product sales when persuasive evidence of a sale exists: that is, a product is shipped under an agreement with a customer; risk of loss and title has passed to the customer; the fee is fixed or determinable; and collection of the resulting receivable is reasonably assured. Sales allowances are estimated based upon historical experience of sales returns. Revenues from product sales are recognized when the product is shipped and title and risk of loss has passed to the customer, typically upon delivery and when the quantity and price is fixed and determinable, and when collectability is reasonable assured. Upfront fees are recognized upon the date of the agreement (i.e. point of sale) because they relate solely to the sale of territories (that are sold in perpetuity), are non-refundable, and are not contingent upon additional deliverables. We have evaluated all deliverables in our contracts (per ASC 605‑25‑5) ((a) territory & (b) manufacturing/marketing training & development fees) and determined that they are separate, as follows: · Both (a) & (b) have value to our customers on a standalone basis and can be sold by our customers separately. · Delivery or performance of the undelivered item or items is considered probable and substantially in our control. Our development fees/milestone payments are recognized in accordance with the Milestone Method pursuant to FASB ASC 605. Revenues from milestones related to an arrangement under which we have continuing performance obligations i.e. specifically scheduled training and development activities, if deemed substantive, are recognized as revenue upon achievement of the milestone. Milestones are considered substantive if all of the following conditions are met: (a) the milestone is non-refundable; (b) achievement of the milestone was not reasonably assured at the inception of the arrangement; (c) substantive effort is involved to achieve the milestone; and (d) the amount of the milestone appears reasonable in relation to the effort expended. If any of these conditions is not met, the milestone payment is deferred and recognized as revenue as we complete our performance obligations. We receive royalty revenues under license agreements with third parties that sell products based on technology developed by us or to which we have rights. The license agreements provide for the payment of royalties to us based on sales of the licensed product. We record these revenues as earned monthly, based on reports from our licensees. Shipping and Handling Shipping and handling costs are included as a component of cost of sales. Shipping and handling costs billed to customers are included in sales. Impairment of Long-Lived Assets Long-lived assets consist primarily of patents and property and equipment. The recoverability of long-lived assets is evaluated by an analysis of operating results and consideration of other significant events or changes in the business environment. If impairment exists, the carrying amount of the long-lived assets is reduced to its estimated fair value, less any costs associated with the final settlement. To date, management has not identified any impairment of property and equipment. There can be no assurance, however, that market conditions or demands for the Company’s services will not change which could result in future long-lived asset impairment. There were no impairment charges during the periods presented. Business Combinations On April 1, 2010, the Company adopted the new accounting guidance for business combinations according to FASB Codification ASC 805, Business Combinations . This guidance establishes principles and requirements for the reporting entity in a business combination, including recognition and measurement in the financial statements of the identifiable assets acquired, the liabilities assumed, goodwill, and any non-controlling interest in the acquire, as well as disclosure requirements to enable financial statement users to evaluate the nature and financial effects of the business combination. Additionally, it provides guidance for identifying a business combination, measuring the acquisition date, and defining the measurement period for adjusting provisional amounts recorded. The implementation of this standard did not have an impact on the Company’s consolidated financial statements. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash or cash equivalents. Non-Controlling Interest The Company adopted ASC Topic 810 Non-controlling Interests in Consolidated Financial Statements — an Amendment of Accounting Research Bulletin No. 51 as of April 1, 2009. SFAS 160 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the non-controlling interest, changes in a parent’s ownership interest and the valuation of retained non-controlling equity investments when a subsidiary is deconsolidated. ASC Topic 810 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interest of the parent and the interests of the non-controlling owner. The adoption of ASC Topic 810 impacted the presentation of our consolidated financial position, results of operations and cash flows. Fair Value of Financial Instruments The Company applies the provisions of accounting guidance, FASB Topic ASC 820 that requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, equity investments, accounts payable andaccrued liabilities. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short maturities of those instruments. The Company’s investment in Condor Technologies (formerly MFI) is accounted for as a financial instrument with a readily determinable fair value and is initially measured at fair value with all subsequent gains and losses recorded in income.The Company adopted the provisions of Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2 – Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other then quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3 – Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment. Accounts Receivable and Allowance for Doubtful Accounts The Company sells professional dental equipment to various companies, primarily to distributors located in Western Europe, Middle East, the United States of America, Asia and China. The terms of sales vary by customer, however, generally are 2% 10 days, net 30 days. Accounts receivable is reported at net realizable value and net of allowance for doubtful accounts. The Company uses the allowance method to account for uncollectible accounts receivable. The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable. Inventories The Company purchases certain of its products in components that require assembly prior to shipment to customers. All other products are purchased as finished goods ready to ship to customers. The Company writes down inventories for estimated obsolescence to estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected, then additional inventory write-downs may be required. Inventory reserves for obsolescence totaled $573,104 at March 31, 2020 and $597,433 at March 31, 2019. Prepaid Expense The Company’s prepaid expense consists of prepayments to suppliers for inventory purchases and to the Belgium customs department, to obtain an exemption of direct VAT payments for imported goods out of the European Union (“EU”). This prepayment serves as a guarantee to obtain the facility to pay VAT at the moment of sale and not at the moment of importing goods at the border. Prepaid expenses also include VAT payments made for goods and services in excess of VAT payments received from the sale of products as well as amounts for other prepaid operating expenses. Property and Equipment Property and equipment are stated at cost. Major renewals and improvements are charged to the asset accounts while replacements, maintenance and repairs, which do not improve or extend the lives of the respective assets, are expensed. At the time property and equipment are retired or otherwise disposed of, the asset and related accumulated depreciation accounts are relieved of the applicable amounts. Gains or losses from retirements or sales are credited or charged to income. The Company depreciates its property and equipment for financial reporting purposes using the straight-line method based upon the following useful lives of the assets: Tooling 3 years Furniture and fixtures 4 years Machinery and Equipment 4 years Patents Patents consist of the costs incurred to purchase patent rights and are reported net of accumulated amortization. Patents are amortized using the straight-line method over a period based on their contractual lives. Research and Development Costs The Company expenses research and development costs as incurred. Advertising Costs incurred for producing and communicating advertising are expensed when incurred and included in sales and marketing and general and administrative expenses. For the years ended March 31, 2020 and March 31, 2019, advertising expense was $38,155 and $138,747, respectively. Income taxes Income taxes are accounted for under the asset and liability method as stipulated by Accounting Standards Codification (“ASC”) 740 formerly Statement of Financial Accounting Standards (“SFAS”) No. 109, “Accounting for Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities or a change in tax rate is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts to be realized by the use of a valuation allowance. A valuation allowance is applied when in management’s view it is more likely than not (50%) that such deferred tax will not be utilized. Effective February 1, 2008, the Company adopted certain provisions under ASC Topic 740, Income Taxes, (“ASC 740”), which provide interpretative guidance for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Effective with the Company’s adoption of these provisions, interest related to the unrecognized tax benefits is recognized in the financial statements as a component of income taxes. The adoption of ASC 740 did not have an impact on the Company’s financial position and results of operations. In the unlikely event that an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by the taxing authorities. Reserves for uncertain tax position would then be recorded if the Company determined it is probable that a position would not be sustained upon examination or if a payment would have to be made to a taxing authority and the amount is reasonably estimable. As of March 31, 2020, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authorities. Warranties The Company typically warrants its products against defects in material and workmanship for a period of 24 months from shipment. A tabular reconciliation of the Company’s aggregate product warranty liability for the reporting period is as follows: Year ended Year ended March 31, 2020 March 31, 2019 Product warranty liability: Opening balance $ 5,619 $ 6,164 Accruals for product warranties issued in the period — — Adjustments to liabilities for pre-existing warranties (123) (545) Ending liability $ 5,496 $ 5,619 Based upon historical trends and warranties provided by the Company’s suppliers and sub-contractors, the Company has made a provision for warranty costs of $5,496 and $5,619 as of March 31, 2020 and March 31, 2019, respectively. Segment Reporting “Disclosure About Segments of an Enterprise and Related Information” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company’s management considers its business to comprise one segment for reporting purposes. Computation of Earnings (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income (loss) per common share attributable to common stockholders assuming dilution is computed by dividing net income by the weighted average number of shares of common stock outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. On April 1, 2009, the Company adopted changes issued by the FASB to the calculation of earnings per share. These changes state that unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method for all periods presented. The adoption of this change had no impact on the Company’s basic or diluted net loss per share because the Company has never issued any share-based awards that contain non-forfeitable rights. At each of March 31, 2020 and 2019, the Company had 19,995,969, shares of common stock issued and outstanding. At March 31, 2020 and 2019, the Company did not have any warrants or options outstanding. Pursuant to ASC 260‑10‑50‑1(c), if a fully diluted share calculation was computed for the years ended March 31, 2020 and 2019 respectively, it would have excluded all options respectively since the Company’s average share trading price during the last two year period was less than the exercise price of all options. Conversion of Foreign Currencies The reporting and functional currency for the consolidated financial statements of the Company is the U.S. dollar. The home currency for the Company’s European subsidiaries, Remedent N.V., Biotech Dental Benelux N.V. GlamSmile Rome and GlamSmile Deutschland GmbH, is the Euro, for Glamsmile Asia Ltd., and its subsidiaries, the Hong Kong dollar and the Chinese Renminbi (“RMB”) for Mainland China. The assets and liabilities of companies whose functional currency is other that the U.S. dollar are included in the consolidation by translating the assets and liabilities at the exchange rates applicable at the end of the reporting period. The statements of income of such companies are translated at the average exchange rates during the applicable period. Translation gains or losses are accumulated as a separate component of stockholders’ equity. Comprehensive Income (Loss) Comprehensive income (loss) includes all changes in equity except those resulting from investments by owners and distributions to owners, including accumulated foreign currency translation, and unrealized gains or losses on ‘Available For Sale (AFS)’ securities. Stock Based Compensation The Company had a stock-based compensation plan which is described more fully in Note 12. The Company measures the compensation cost of stock options and other stock-based awards to employees and directors at fair value at the grant date and recognizes compensation expense over the requisite service period for awards expected to vest. Except for transactions with employees and directors, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Additionally, the Company has determined that the dates used to value the transaction are either: (1) The date at which a commitment for performance by the counter party to earn the equity instruments is established; or (2) The date at which the counter party’s performance is complete. Risk Management The Company’s credit risk is primarily attributable to its accounts receivable. The amounts presented in the accompanying consolidated balance sheets are net of allowances for doubtful accounts, estimated by the Company’s management based on prior experience and the current economic environment. The Company is exposed to credit-related losses in the event of non-payment by customers. Credit exposure is minimized by dealing with only credit worthy counterparties. Accounts receivable for the Company’s five primary customers totaled $53,647 or 11.09% at March 31, 2020 (March 31, 2019 - $92,409 or 23.59%). The credit risk on cash and cash equivalents is limited because the Company limits its exposure to credit loss by placing its cash and cash equivalents with major financial institutions. The Company has not experienced any material losses in such accounts. The Company is exposed to foreign exchange and interest rate risk to the extent that market value rate fluctuations materially differ from financial assets and liabilities, subject to fixed long-term rates. In order to manage its exposure to foreign exchange risks, the Company is closely monitoring the fluctuations in the foreign currency exchange rates and the impact on the value of cash and cash equivalents, accounts receivable, and accounts payable and accrued liabilities. The Company has not hedged its exposure to currency fluctuations. Equity Method Investment The Company accounts for investments using the equity method of accounting if the investment provides the Company the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company’s ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is recorded at cost in the consolidated balance sheets under other assets and adjusted for dividends received and the Company’s share of the investee’s earnings or losses together with other-than-temporary impairments which are recorded through interest and other loss, net in the consolidated statements of income and comprehensive income. Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations. Adopted Accounting Pronouncements In February 2016, the FASB established ASU Topic 842 – Leases, by issuing ASU Topic No. 2016-02 (“Topic 842”), which requires lessees to recognize lease on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU Topic 2018-11 – Targeted Improvements. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and a lease liability for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted Topic 842 in the first quarter of 2019 utilizing the modified retrospective transition method and a cumulative effect adjustment at the beginning of the first quarter of 2019. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date, and (3) initial direct costs for any existing leases as of the adoption date. The Company did not elect to apply the hindsight practical expedient when determining lease term and assessing impairment of the right-to-use assets. The adoption of Topic 842 resulted in the recognition of right-of use assets of approximately $180,926 and lease liabilities for operating leases of approximately $180,926 and no cumulative effect adjustment on retained earnings on its unaudited Consolidated Balance Sheets or material impact to its unaudited Consolidated Statements of Operations and Comprehensive Loss in the period of adoption. Right-of-use assets are included in Prepaid and other assets, and lease liabilities are included in Accrued liabilities in the consolidated balance sheet. See Note 14 — Leases, for additional information.

LONG-TERM INVESTMENTS

LONG-TERM INVESTMENTS	12 Months Ended
	Mar. 31, 2020
LONG-TERM INVESTMENTS
LONG-TERM INVESTMENTS	3 . LONG-TERM INVESTMENTS GLAMSMILE ASIA LTD. Acquisition Effective January 1, 2010 the Company acquired 50.98% of the issued and outstanding shares of Glamsmile Asia Ltd. (“Glamsmile Asia” or “Glamsmile”), a private Hong Kong company, with subsidiaries in Hong Kong and Mainland China, in exchange for the following consideration: 1. 325,000 Euro (US$466,725). As of March 31, 2011 the full amount was paid. 2. 250,000 shares of common stock to be issued during the fiscal year ended March 31, 2011($97,500 was recorded as an obligation to issue shares as at March 31, 2010). The parties have agreed that the shares will be issued during fiscal year ended March 31, 2016. 3. 100,000 options on closing (issued); 4. 100,000 options per opened store at closing (issued); 5. 100,000 options for each additional store opened before the end of 2011 at the price of the opening date of the store; 6. Assumption of Glamsmile’s January 1, 2010 deficit of $73,302.; and 7. Repayment of the founding shareholder’s original advances in the amount of $196,599. The balance of $196,599, recorded as due to related parties at March 31, 2010, is unsecured, non-interest bearing and has no specific terms of repayment other than it will be paid out of revenues from Glamsmile, as working capital allows. During the year ended March 31, 2011 a total of $101,245 was paid to the founding shareholder, leaving a balance due of $95,354 on June 27, 2011. As at March 31, 2012 the full amount was paid. All options resided under the Company’s option plan and were five year options which expired as of 2016. Also pursuant to the agreement, the Company granted irrevocable right to Glamsmile Asia to use the Glamsmile trademark in Greater China. The Company acquired a 50.98% interest in GlamSmile Asia Ltd. (“GlamSmile Asia”) in order to obtain a platform in the Chinese Market to expand and introduce our GlamSmile Asia concept into the Chinese Market. In order to sell into the Chinese Market, an approval by Chinese Authorities is required, in the form of licenses. As GlamSmile Asia was already the owner of such licenses prior to the acquisition, this was an important advantage. We obtained control of GlamSmile Asia through the acquisition of the 50.98% interest and the appointment of our CEO as a Board member of GlamSmile Asia. On January 30, 2014, the Company sold a total of 2,500,000 ordinary shares of its investment in GlamSmile Dental Technology Ltd for $3,000,000 and recognized a gain on the sale in the amount of $1,582,597. As of March 31, 2014 the Company has received $1,850,000 and has recorded the balance of $1,150,000 as an amount receivable. Effective March 31, 2014 the Company has retained a 21.51% ownership in GlamSmile Asia Ltd. The Company has measured its 21.51% ownership in GlamSmile Asia Ltd. at historical cost. As of March 31, 2020, the investment in GlamSmile Asia was fair valued using the income approach and no impairment indicators have been identified. The recent impact of COVID-19 has caused a short-term delay in sales which is currently normalizing to pre-COVID-19 levels. Deconsolidation On January 28, 2012, the Company entered into a Preference A Shares and Preference A‑1 Shares Purchase Agreement (“Share Purchase Agreement”) with Glamsmile Dental Technology Ltd., a Cayman Islands company and a subsidiary of the Company (“Glamsmile Dental”), Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong and a substantially owned subsidiary of Glamsmile Dental, Beijing Glamsmile Technology Development Ltd., Beijing Glamsmile Trading Co., Ltd., Beijing Glamsmile Dental Clinic Co., Ltd., and Shanghai Glamsmile Dental Clinic Co., Ltd., Gallant Network Limited, a shareholder of Glamsmile Dental (“Gallant”), and IDG-Accel China Growth Fund III L.P. (“IDG Growth”), IDG-Accel China III Investors L.P.(“IDG Investors”) and Crown Link Group Limited (“Crown”)(“IDG Growth, IDG Investors and Crown collectively referred to as the “Investors”), pursuant to which the Investors agreed to (i) purchase from the Company an aggregate of 2,857,143 shares of Preference A‑1 Shares of Glamsmile Dental, which represents all of the issued and outstanding Preference A‑1 Shares of Glamsmile Dental, for an aggregate purchase price of $2,000,000, and (ii) purchase from Glamsmile Dental an aggregate of 5,000,000 shares of Preference A Shares for an aggregate purchase price of $5,000,000. Under the terms of the Share Purchase Agreement, the Company agreed (a) to indemnify the Investors and their respective affiliates for losses arising out of a breach, or inaccuracy or misrepresentation in any representation or warranty made by the Company or a breach or violation of a covenant or agreement made by the Company for up to $1,500,000, and (b) to transfer 500,000 shares of Glamsmile Dental owned by the Company to the Investors in the event of breach of certain covenants by the Company. In connection with the Share Purchase Agreement, the Company also agreed to enter into an Investor’s Rights Agreement, Right of First Refusal and Co-Sale Agreement, and Voting Agreement with the parties. In addition, in connection with the contemplated transactions in the Share Purchase Agreement on January 20, 2012, the Company entered into a Distribution, License and Manufacturing Agreement with Glamsmile Dental pursuant to which the Company appointed Glamsmile Dental as the exclusive distributor and licensee of Glamsmile Veneer Products bearing the “Glamsmile” name and mark in the B2C Market in the People’s Republic of China (including Hong Kong and Macau) and Republic of China (Taiwan) and granted related manufacturing rights and licenses in exchange for the original issuance of 2,857,143 shares of Preference A‑1 Shares of Glamsmile Dental and $250,000 (the receipt of which was acknowledged as an offset to payment of certain invoices of Glamsmile (Asia) Limited). On February 10, 2012, the sale of the Preference A‑1 Shares and the Preference A Shares was completed. As a result of the closing, the equity ownership of Glamsmile Dental, on an as converted basis, is as follows: 31.4% by the Investors, 39.2 % by Gallant, and 29.4% by the Company. Mr. De Vreese, our chairman, will remain as a director of Glamsmile Dental along with Mr. David Lok, who is the Chief Executive Officer and director of Glamsmile Dental and principal of Gallant. The Investors have a right to appoint one director of Glamsmile Dental, and accordingly the Board of Directors of Glamsmile Dental will consist of Mr. De Vreese, Mr. Lok and a director appointed by the Investors. In conjunction with the transaction and resulting deconsolidation of Glamsmile Dental, the Company recorded a gain of $1,470,776, calculated as follows: Consideration received $ 2,000,000 Fair value of 29.4% interest 2,055,884 Carrying value of non-controlling interest 1,117,938 Less: carrying value of former subsidiary’s net assets (2,002,329) Goodwill (699,635) Investment China & Hong Kong (1,082) Rescission agreement Excelsior (1,000,000) $ 1,470,776 For the year ended March 31, 2020, the Company recorded an equity (loss) income of $(156,093) (2019 – equity income of $61,680) in “Equity income from investments” for its portion of the net loss recorded by GlamSmile Dental Technology Ltd. As at March 31, 2020 and March 31, 2019, unrealized net gains (loss) were $(156,093) and $61,680 respectively. The following tables represent the summary financial information of GlamSmile Asia as derived from its financial statements and prepared under US GAAP: Operating data: March 31, 2020 March 31, 2019 Revenues $ 4,026,904 $ 4,644,421 Gross profit 2,510,269 3,952,082 Income (loss) from operations (630,811) 380,539 Net income (loss) $ (725,675) $ 286,752 CONDOR TECHNOLOGIES (formerly Medical Franchises & Investments (“MFI”) Effective March 31, 2013, the Company acquired 6.12% of the issued and outstanding shares of Medical Franchises & Investments N.V., a Belgium corporation ("Condor Technologies NV") in exchange for a cash prepayment of $314,778 that was made during the fiscal year ended March 31, 2012. The Company’s investment in 70,334 shares of MFI NV has been recorded at the fair value of $787,339 which is the quoted market price of approximately USD $11.19 (€8.70) per share. As a result of our adoption of ASU 2016‑01, the investment is being recognized as a financial instrument with a readily determinable fair value and an unrecognized loss of $(176,119) has been recorded in income due to the fair value per share at March 31, 2020, being $16.49 (€15,00) per share. Further, as a result of our adoption of ASU 2016‑01, we have recorded a transition date adjustment as at April 1, 2018 to reclassify the unrecognized profit of $178,361 recorded in 2018 from other comprehensive income to deficit. MFI NV has been founded to market an advance in dental technology which has the potential to replace the process of making mechanical impressions of teeth and bite structures with a digital/optical scan. During November 2016, the name of the Company MFI NV was changed and renamed to Condor Technologies NV. METRICS IN BALANCE N.V. Effective November 22, 2018, the Company acquired 63,112 shares or 3.08% of the issued and outstanding shares of Metrics in Balance N.V., a Belgium Corporation (“MIB”). As of March 29, 2019, our 60% ownership of SmileWise was merged into MIB, and we converted cash payments to MIB of $123,912 (€ 110,271) to MIB shares; resulting in an increased in our shareholding of MIB by 1,082,190 shares to a total of 1,145,302 or 26.09%. MIB listed on the Euronext, Paris, France in March 2018 and trading has been minimal to date. Consequently, the quoted market price has not been disclosed because it may not be representative of the fair value of our investment. MIB has been founded to allow healthcare and dental professionals to determine the relationship between malocclusion and posture problems thereby enabling therapy to improve quality of life. As a result of the increase in share ownership the Company has determined that significant control exists and consequently the investment is being recorded as an equity investment and all gains or losses are recorded in income. During the year ended March 31, 2020 we have recorded a loss of $(21,413). During the year ended March 31, 2019 we have recorded $2,832,822 in equity income comprised of a gain on merger of SmileWise in the amount of $3,007,301 resulting from the re-measurement of the value of SmileWise, offset by an equity loss of $174,479. SmileWise was fair valued using an average of discounted cash flow and comparable exit methods employing the following inputs: discounted cash flows using a weighted average cost of capital (“WAAC”) of 23%; software as a service (“SaaS”) multiples, dental industry multiples and mergers and acquisition (“M&A”) multiples of between 5.1 and 18.5. As at March 31, 2020 and March 31, 2019 unrealized net gains (loss) on our investment in MIB were$(21,413) and $2,832,822 respectively. The recent impact of COVID-19 has caused a short-term delay in sales which is currently normalizing to pre-COVID-19 levels. The following tables represent the summary financial information of MIB as derived from its financial statements and prepared under US GAAP: Operating data: March 31, 2020 March 31, 2019 Revenues $ 58,441 $ 12,307 Gross profit 57,951 10,544 Income (loss) from operations (96,846) (322,463) Net income (loss) $ (82,071) $ (327,793) SMILEWISE CORPORATE B.V.B.A. Effective April 16, 2018, the Company acquired 60% of the issued and outstanding shares of SmileWise Corporate B.V.B.A., a Belgium corporation (“SmileWise’) in exchange for a cash payment of $2,592 (€2,226) that was made during April 2018. As of March 29, 2019, 100% of SmileWise was merged into MIB. This merger/integration was completed because SmileWise needed a new ‘practice-building’ clinical concept and MIB needed a team to fill the clinics with patients. SmileWise is a dental marketing agency and software developer catering to dentists.

CONCENTRATION OF RISK

CONCENTRATION OF RISK	12 Months Ended
	Mar. 31, 2020
CONCENTRATION OF RISK
CONCENTRATION OF RISK	4. CONCENTRATION OF RISK Financial Instruments — Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade accounts receivable. Concentrations of credit risk with respect to trade receivables are normally limited due to the number of customers comprising the Company’s customer base and their dispersion across different geographic areas. At March 31, 2020five customers accounted for a total of 11.09% of the Company’s trade accounts receivable and one of those customers accounted for 2.89% of total accounts receivable. The Company performs ongoing credit evaluations of its customers and normally does not require collateral to support accounts receivable. At March 31, 2019 five customers accounted for a total of 23.59% of the Company’s trade accounts receivable and one of those customers accounted for 6.93% of total accounts receivable. Purchases — The Company has diversified its sources for product components and finished goods and, as a result, the loss of a supplier would not have a material impact on the Company’s operations. As at March 31, 2020, the Company had five suppliers who accounted for 40.15% of unpaid accounts payable and one of those customers accounted for 36.29% of total unpaid accounts payable. As at March 31, 2019, the Company had five suppliers who accounted for 48.86% of unpaid accounts payable and one of those suppliers accounted for 42.18% of total unpaid accounts payable. Revenues — For the year ended March 31, 2020 the Company had five customers that accounted for 26.30% of total revenues and one of those customers accounted for 9.07% of total revenues. For the year ended March 31, 2019 the Company had five customers that accounted for 64.48% of total revenues and one of those customers accounted for 22.90% of total revenues.

ACCOUNTS RECEIVABLE AND ALLOWAN

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS	12 Months Ended
	Mar. 31, 2020
ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS
ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS	5. ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS The Company’s accounts receivable at year end were as follows: March 31, 2020 March 31, 2019 Accounts receivable, gross $ 483,787 $ 391,811 Less: allowance for doubtful accounts (154,447) (157,903) Accounts receivable, net $ 329,340 $ 233,908

INVENTORIES

INVENTORIES	12 Months Ended
	Mar. 31, 2020
INVENTORIES
INVENTORIES	6. INVENTORIES Inventories at year end are stated at the lower of cost (first-in, first-out) or net realizable value and consisted of the following: March 31, 2020 March 31, 2019 Raw materials $ 7,483 $ 9,151 Components 91,808 121,941 Finished goods 564,654 577,303 663,945 708,395 Less: reserve for obsolescence (573,104) (597,433) Net inventory $ 90,841 $ 110,962

PREPAID EXPENSES

PREPAID EXPENSES	12 Months Ended
	Mar. 31, 2019
PREPAID EXPENSES
PREPAID EXPENSES	7. PREPAID EXPENSES Prepaid expenses are summarized as follows: March 31, 2020 March 31, 2019 Prepaid materials and components $ 51,050 $ 217,172 Prepaid trade show expense — 4,933 VAT payments in excess of VAT receipts 3,947 7,355 Other 4,418 15,064 Right-of-use assets 86,834 — $ 146,249 $ 244,524

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Mar. 31, 2020
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT	8. PROPERTY AND EQUIPMENT Property and equipment are summarized as follows: March 31, 2020 March 31, 2019 Furniture and Fixtures $ 480,252 $ 478,406 Machinery and Equipment 1,917,825 2,154,822 2,398,077 2,633,228 Accumulated depreciation (2,330,985) (2,507,495) Property & equipment, net $ 67,092 $ 125,733

DUE TO RELATED PARTIES AND RELA

DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS	12 Months Ended
	Mar. 31, 2020
DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS
DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS	9. DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS Transactions with related parties not disclosed elsewhere in these financial statements consisted of the following: Compensation: During the years ended March 31, 2020 and 2019 respectively, the Company incurred $192,758 and $221,130 respectively as compensation for all directors and officers. All related party transactions involving provision of services or tangible assets were recorded at the exchange amount, which is the value established and agreed to by the related parties reflecting arm’s length consideration payable for similar services or transfers.

ACCRUED LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Mar. 31, 2020
ACCRUED LIABILITIES
ACCRUED LIABILITIES	10. ACCRUED LIABILITIES Accrued liabilities are summarized as follows: March 31, 2020 March 31, 2019 Accrued employee benefit taxes and payroll $ 102,207 $ 176,858 Accrued travel 5,496 5,619 Accrued audit and tax preparation fees 17,395 23,255 Reserve for warranty costs 5,496 5,619 Accrued commission 15,000 — Accrued consulting fees 196,633 179,669 Tax reserve 5,630 753 VAT to be paid 7,997 7,462 Other accrued expenses + lease liability 130,909 51,112 $ 486,763 $ 450,347

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2020
INCOME TAXES
INCOME TAXES	11. INCOME TAXES The domestic and foreign (“Belgium”, “German”, “Italian”, Hong Kong and China) components of income (loss) before income taxes and minority interest were comprised of the following: March 31, 2020 March 31, 2019 Domestic $ (354,913) $ (655,273) Foreign (497,025) 2,775,270 $ (851,938) $ 2,119,997 The Company’s domestic and foreign components of deferred income taxes are as follows: March 31, 2020 March 31, 2019 Domestic — Net operating loss carryforward $ 8,680,733 $ 7,984,906 Foreign — Net operating loss carryforward (682,511) (831,619) Total 7,998,222 7,153,287 Valuation allowance (7,998,222) (7,153,287) Net deferred tax assets $ — $ — Because of the uncertainty surrounding the timing of realizing the benefits of favorable tax attributes in future income tax returns, the Company has placed a valuation allowance against its deferred income tax assets. The principal reasons for the difference between the income tax (benefit) and the amounts computed by applying the statutory income tax rates to the income (loss) for the year ended March 31, 2020 and March 31, 2019 are as follows: March 31, 2020 March 31, 2019 Domestic Pre tax income (loss) $ (354,913) $ (655,273) Statutory tax rate 27 % 27 % Tax benefit based upon statutory rate (95,827) (176,924) Valuation allowance 95,827 176,924 Net domestic income tax (benefit) — — Foreign Pre tax income (loss) (497,025) 2,775,270 Statutory tax rate 30 % 30 % Tax expense (benefit) based upon statutory rate (149,108) 832,581 Permanent differences 149,108 (832,581) — — Net foreign income tax expense (recovery) 2,329 874 Total Income tax expense (recovery) $ 2,329 $ 874

EQUITY COMPENSATION PLANS

EQUITY COMPENSATION PLANS	12 Months Ended
	Mar. 31, 2020
EQUITY COMPENSATION PLANS
EQUITY COMPENSATION PLANS	12. EQUITY COMPENSATION PLANS As of March 31, 2020, the Company had two equity compensation plans approved by its stockholders (1) the 2004 Incentive and Non-statutory Stock Option Plan (the “2004 Plan”); and (2) the 2007 Equity Incentive Plan (the “2007 Plan”). The Company’s stockholders approved the 2004 Plan reserving 800,000 shares of common stock of the Company pursuant to an Information Statement on Schedule 14C filed with the Commission on May 9, 2005. Finally, the Company’s stockholders approved the 2007 Plan reserving 1,000,000 shares of common stock of the Company pursuant to a Definitive Proxy Statement on Schedule 14A filed with the Commission on October 2, 2007. In addition to the equity compensation plans approved by the Company’s stockholders, the Company has issued options and warrants to individuals pursuant to individual compensation plans not approved by our stockholders. These options and warrants have been issued in exchange for services or goods received by the Company. The following table provides aggregate information as of March 31, 2020 and March 31, 2019 with respect to all compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance. 2004 Plan 2007 Plan Weighted Weighted Average Average Outstanding Exercise Outstanding Exercise Options Price Options Price Options outstanding and exercisable March 31, 2018 357,500 0.50 430,000 1.21 Options expired (357,500) (430,000) Options outstanding and exercisable at March 31, 2020 and March 31, 2019 — — A summary of the Company’s equity compensation plans approved and not approved by shareholders is as follows: Number of securities remaining available for future Number of issuance securities to under be equity issued upon Weighted-average compensation exercise of exercise price of plans outstanding outstanding (excluding options, options securities warrants warrants and reflected Plan Category and rights rights in column (a)) Equity Compensation Plans approved by security holders — $ — 1,962,500 For the years ended March 31, 2020 and March 31, 2019 the Company has not recognized any stock based compensation expense in the consolidated statement of operations. No stock options were granted in the years ended March 31, 2020 and March 31, 2019. As of March 31, 2020 and March 31, 2019 all of the Company’s previously outstanding stock options have expired unexercised.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Mar. 31, 2020
SEGMENT INFORMATION
SEGMENT INFORMATION	13. SEGMENT INFORMATION The Company’s only operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Condor North America LLC., Remedent N.V., and Biotech Dental Benelux N.V. in the year ended March 31, 2020 and the year ended March 31, 2019. Our operations are primarily in Europe and Asia and 100% of our sales for the fiscal year ended March 31, 2020 and 100% of our sales for the fiscal year ended March 31, 2019 were generated from customers outside of the United States.

LEASES

LEASES	12 Months Ended
	Mar. 31, 2020
LEASES
LEASES	14. LEASES The Company enters into operating leases primarily for real estate, office equipment and vehicles. Lease terms generally range from four to nine years. On April 1, 2019, the Company adopted Topic 842, using the modified-retrospective approach as discussed in Note 2, and as a result, recognized a right-of-use asset of $170,898 and a lease liability of $170,898. No cumulative-effect adjustment to retained earnings was required upon adoption of Topic 842. Right-of use-assets are recorded in prepaid expenses and other current assets and lease liabilities are recorded in accrued liabilities or other liabilities depending on whether they are current or noncurrent.. The Company uses a 12% rate to determine the present value of the lease payments. Information related to the Company’s right-of-use assets and related liabilities were as follows: March 31, 2020 Cash paid for operating lease liabilities $ 103,370 Right-of-use assets obtained in exchange for new operating lease obligations Weighted-average remaining lease term, real estate 0.75 years Weighted-average remaining lease term, all other leased equipment 1.84 years Weighted-average discount rate 12 % The Company excludes short-term leases (those with lease terms of less than one year at inception) from the measurement of lease liabilities or right-of-use assets. Maturities of lease liabilities as of March 31, 2020, were as follows: Due in 12-month period ended March 31: 2021 $ 85,550 Thereafter 5,569 $ 91,119 Less imputed interest (4,285) Total lease liabilities $ 86,834 Current operating lease liabilities $ 81,379 Non-current lease liabilities 5,455 Total lease liabilities $ 86,834 As of March 31, 2020, right-of-use assets were $86,834 and lease liabilities were $86,834. During the year ended March 31, 2020, the Company did not enter into any new lease arrangements, and did not have any arrangements that had not yet commenced.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	12 Months Ended
	Mar. 31, 2020
FINANCIAL INSTRUMENTS
FINANCIAL INSTRUMENTS	15. FINANCIAL INSTRUMENTS The FASB ASC topic 820 on fair value measurement and disclosures establishes three levels of inputs that may be used to measure fair value: quoted prices in active markets for identical assets or liabilities (referred to as Level 1), observable inputs other than Level 1 that are observable for the asset or liability either directly or indirectly (referred to as Level 2), and unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities (referred to as Level 3). The carrying values and fair values of our financial instruments are as follows: March 31, 2020 March 31, 2019 Carrying Fair Carrying Fair Level value Value value value Cash 1 114,634 $ 114,634 $ 66,539 $ 66,539 Accounts receivable 2 329,340 $ 329,340 $ 233,908 $ 233,908 Long Term investment and advance - GlamSmile Dental Technology Asia 3 2,150,724 $ 2,150,724 $ 2,306,817 $ 2,306,817 Long term investments and advances Condor 1 1,159,561 $ 1,159,561 $ 1,335,680 $ 1,335,680 Long term investment in Metrics in Balance 1 3,450,598 $ 3,450,598 3,472,011 3,472,011 Deferred revenue 2 100,571 $ 100,571 $ 63,852 $ 63,852 Accounts payable 2 2,294,884 $ 2,294,884 $ 1,919,095 $ 1,919,095 Accrued liabilities 2 486,763 $ 486,763 $ 450,347 $ 450,347 The following method was used to estimate the fair values of our financial instruments: The carrying amount of level 1 and level 2 financial instruments approximates fair value because of the short maturity of the instruments. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 financial assets also include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no significant transfers between Level 1, Level 2, or Level 3 during the fiscal years ended March 31, 2020 or March 31, 2019. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following table provides a reconciliation of the beginning and ending balances of the item measured at fair value on a recurring basis in the table above that used significant unobservable inputs (Level 2): Year ended March 31, Year ended March 31, 2020 2019 Long term investments and advances: Beginning balance $ 2,306,817 $ 2,245,137 Gains (losses) included in net loss (156,093) 61,680 Transfers in (out of level 3) — — Ending balance $ 2,150,724 $ 2,306,817 Fair values for Level 3 assets are determined based upon management’s cash flow projections.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization and Principles of Consolidation	Organization and Principles of Consolidation The accompanying consolidated financial statements include the accounts of: Remedent N.V. (incorporated in Belgium) located in Ghent, Belgium, Remedent Professional, Inc. and Remedent Professional Holdings, Inc. (both incorporated in California and inactive), Glamtech-USA, Inc. (a Delaware corporation acquired effective August 24, 2008), Condor North America LLC, a Nevada corporation, Remedent N.V.’s 50% owned subsidiary, Biotech Dental Benelux N.V., a Belgium private company located in Ghent, Remedent N.V.’s 51% owned subsidiary, GlamSmile Deutschland GmbH, a German private company located in Munich (effective March 31, 2014 this subsidiary is inactive), Remedent N.V.’s 80% owned subsidiary, GlamSmile Rome, an Italian private company located in Rome (effective March 31, 2014 this subsidiary is inactive) Remedent N.V. owns 21.51 % of Glamsmile Dental Technology Ltd., a Cayman Islands company (“Glamsmile Dental”). The subsidiaries of Glamsmile Dental include: Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong, Beijing Glamsmile Technology Development Ltd., a 100% owned subsidiary or GlamSmile Asia, its 80% owned subsidiary Beijing Glamsmile Trading Co., Ltd. and its 98% owned subsidiary Beijing Glamsmile Dental Clinic Co., Ltd., including its 100% owned Shanghai Glamsmile Dental Clinic Co., Ltd., its 100% owned Guangzhou Dental Clinic Co., Ltd. and its 50% owned Whenzhou GlamSmile Dental Clinic Ltd., which are accounted for using the equity method after January 31, 2012 (see Note 3 – Long-term Investment) Remedent, Inc. is a holding company with headquarters in Ghent, Belgium. Remedent Professional, Inc. and Remedent Professional Holdings, Inc. have been dormant since inception. For all periods presented, all significant inter-company accounts and transactions have been eliminated in the consolidated financial statements and corporate administrative costs are not allocated to subsidiaries.
Pervasiveness of Estimates	Pervasiveness of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, the Company evaluates estimates and judgments, including those related to revenue, bad debts, inventories, fixed assets, intangible assets, stock based compensation, income taxes, and contingencies. Estimates are based on historical experience and on various other assumptions that the Company believes reasonable in the circumstances. The results form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when persuasive evidence of a sale exists: that is, a product is shipped under an agreement with a customer; risk of loss and title has passed to the customer; the fee is fixed or determinable; and collection of the resulting receivable is reasonably assured. Sales allowances are estimated based upon historical experience of sales returns. Revenues from product sales are recognized when the product is shipped and title and risk of loss has passed to the customer, typically upon delivery and when the quantity and price is fixed and determinable, and when collectability is reasonable assured. Upfront fees are recognized upon the date of the agreement (i.e. point of sale) because they relate solely to the sale of territories (that are sold in perpetuity), are non-refundable, and are not contingent upon additional deliverables. We have evaluated all deliverables in our contracts (per ASC 605‑25‑5) ((a) territory & (b) manufacturing/marketing training & development fees) and determined that they are separate, as follows: · Both (a) & (b) have value to our customers on a standalone basis and can be sold by our customers separately. · Delivery or performance of the undelivered item or items is considered probable and substantially in our control. Our development fees/milestone payments are recognized in accordance with the Milestone Method pursuant to FASB ASC 605. Revenues from milestones related to an arrangement under which we have continuing performance obligations i.e. specifically scheduled training and development activities, if deemed substantive, are recognized as revenue upon achievement of the milestone. Milestones are considered substantive if all of the following conditions are met: (a) the milestone is non-refundable; (b) achievement of the milestone was not reasonably assured at the inception of the arrangement; (c) substantive effort is involved to achieve the milestone; and (d) the amount of the milestone appears reasonable in relation to the effort expended. If any of these conditions is not met, the milestone payment is deferred and recognized as revenue as we complete our performance obligations. We receive royalty revenues under license agreements with third parties that sell products based on technology developed by us or to which we have rights. The license agreements provide for the payment of royalties to us based on sales of the licensed product. We record these revenues as earned monthly, based on reports from our licensees.
Shipping and Handling	Shipping and Handling Shipping and handling costs are included as a component of cost of sales. Shipping and handling costs billed to customers are included in sales.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets consist primarily of patents and property and equipment. The recoverability of long-lived assets is evaluated by an analysis of operating results and consideration of other significant events or changes in the business environment. If impairment exists, the carrying amount of the long-lived assets is reduced to its estimated fair value, less any costs associated with the final settlement. To date, management has not identified any impairment of property and equipment. There can be no assurance, however, that market conditions or demands for the Company’s services will not change which could result in future long-lived asset impairment. There were no impairment charges during the periods presented.
Business Combinations	Business Combinations On April 1, 2010, the Company adopted the new accounting guidance for business combinations according to FASB Codification ASC 805, Business Combinations . This guidance establishes principles and requirements for the reporting entity in a business combination, including recognition and measurement in the financial statements of the identifiable assets acquired, the liabilities assumed, goodwill, and any non-controlling interest in the acquire, as well as disclosure requirements to enable financial statement users to evaluate the nature and financial effects of the business combination. Additionally, it provides guidance for identifying a business combination, measuring the acquisition date, and defining the measurement period for adjusting provisional amounts recorded. The implementation of this standard did not have an impact on the Company’s consolidated financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash or cash equivalents.
Non-Controlling Interest	Non-Controlling Interest The Company adopted ASC Topic 810 Non-controlling Interests in Consolidated Financial Statements — an Amendment of Accounting Research Bulletin No. 51 as of April 1, 2009. SFAS 160 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the non-controlling interest, changes in a parent’s ownership interest and the valuation of retained non-controlling equity investments when a subsidiary is deconsolidated. ASC Topic 810 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interest of the parent and the interests of the non-controlling owner. The adoption of ASC Topic 810 impacted the presentation of our consolidated financial position, results of operations and cash flows.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company applies the provisions of accounting guidance, FASB Topic ASC 820 that requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, equity investments, accounts payable andaccrued liabilities. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short maturities of those instruments. The Company’s investment in Condor Technologies (formerly MFI) is accounted for as a financial instrument with a readily determinable fair value and is initially measured at fair value with all subsequent gains and losses recorded in income.The Company adopted the provisions of Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2 – Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other then quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3 – Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts The Company sells professional dental equipment to various companies, primarily to distributors located in Western Europe, Middle East, the United States of America, Asia and China. The terms of sales vary by customer, however, generally are 2% 10 days, net 30 days. Accounts receivable is reported at net realizable value and net of allowance for doubtful accounts. The Company uses the allowance method to account for uncollectible accounts receivable. The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable.
Inventories	Inventories The Company purchases certain of its products in components that require assembly prior to shipment to customers. All other products are purchased as finished goods ready to ship to customers. The Company writes down inventories for estimated obsolescence to estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected, then additional inventory write-downs may be required. Inventory reserves for obsolescence totaled $573,104 at March 31, 2020 and $597,433 at March 31, 2019.
Prepaid Expense	Prepaid Expense The Company’s prepaid expense consists of prepayments to suppliers for inventory purchases and to the Belgium customs department, to obtain an exemption of direct VAT payments for imported goods out of the European Union (“EU”). This prepayment serves as a guarantee to obtain the facility to pay VAT at the moment of sale and not at the moment of importing goods at the border. Prepaid expenses also include VAT payments made for goods and services in excess of VAT payments received from the sale of products as well as amounts for other prepaid operating expenses.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Major renewals and improvements are charged to the asset accounts while replacements, maintenance and repairs, which do not improve or extend the lives of the respective assets, are expensed. At the time property and equipment are retired or otherwise disposed of, the asset and related accumulated depreciation accounts are relieved of the applicable amounts. Gains or losses from retirements or sales are credited or charged to income. The Company depreciates its property and equipment for financial reporting purposes using the straight-line method based upon the following useful lives of the assets: Tooling 3 years Furniture and fixtures 4 years Machinery and Equipment 4 years
Patents	Patents Patents consist of the costs incurred to purchase patent rights and are reported net of accumulated amortization. Patents are amortized using the straight-line method over a period based on their contractual lives.
Research and Development Costs	Research and Development Costs The Company expenses research and development costs as incurred.
Advertising	Advertising Costs incurred for producing and communicating advertising are expensed when incurred and included in sales and marketing and general and administrative expenses. For the years ended March 31, 2020 and March 31, 2019, advertising expense was $38,155 and $138,747, respectively.
Income taxes	Income taxes Income taxes are accounted for under the asset and liability method as stipulated by Accounting Standards Codification (“ASC”) 740 formerly Statement of Financial Accounting Standards (“SFAS”) No. 109, “Accounting for Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities or a change in tax rate is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts to be realized by the use of a valuation allowance. A valuation allowance is applied when in management’s view it is more likely than not (50%) that such deferred tax will not be utilized. Effective February 1, 2008, the Company adopted certain provisions under ASC Topic 740, Income Taxes, (“ASC 740”), which provide interpretative guidance for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Effective with the Company’s adoption of these provisions, interest related to the unrecognized tax benefits is recognized in the financial statements as a component of income taxes. The adoption of ASC 740 did not have an impact on the Company’s financial position and results of operations. In the unlikely event that an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by the taxing authorities. Reserves for uncertain tax position would then be recorded if the Company determined it is probable that a position would not be sustained upon examination or if a payment would have to be made to a taxing authority and the amount is reasonably estimable. As of March 31, 2020, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authorities.
Warranties	Warranties The Company typically warrants its products against defects in material and workmanship for a period of 24 months from shipment. A tabular reconciliation of the Company’s aggregate product warranty liability for the reporting period is as follows: Year ended Year ended March 31, 2020 March 31, 2019 Product warranty liability: Opening balance $ 5,619 $ 6,164 Accruals for product warranties issued in the period — — Adjustments to liabilities for pre-existing warranties (123) (545) Ending liability $ 5,496 $ 5,619 Based upon historical trends and warranties provided by the Company’s suppliers and sub-contractors, the Company has made a provision for warranty costs of $5,496 and $5,619 as of March 31, 2020 and March 31, 2019, respectively.
Segment Reporting	Segment Reporting “Disclosure About Segments of an Enterprise and Related Information” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company’s management considers its business to comprise one segment for reporting purposes.
Computation of Earnings (Loss) per Share	Computation of Earnings (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income (loss) per common share attributable to common stockholders assuming dilution is computed by dividing net income by the weighted average number of shares of common stock outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. On April 1, 2009, the Company adopted changes issued by the FASB to the calculation of earnings per share. These changes state that unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method for all periods presented. The adoption of this change had no impact on the Company’s basic or diluted net loss per share because the Company has never issued any share-based awards that contain non-forfeitable rights. At each of March 31, 2020 and 2019, the Company had 19,995,969, shares of common stock issued and outstanding. At March 31, 2020 and 2019, the Company did not have any warrants or options outstanding. Pursuant to ASC 260‑10‑50‑1(c), if a fully diluted share calculation was computed for the years ended March 31, 2020 and 2019 respectively, it would have excluded all options respectively since the Company’s average share trading price during the last two year period was less than the exercise price of all options.
Conversion of Foreign Currencies	Conversion of Foreign Currencies The reporting and functional currency for the consolidated financial statements of the Company is the U.S. dollar. The home currency for the Company’s European subsidiaries, Remedent N.V., Biotech Dental Benelux N.V. GlamSmile Rome and GlamSmile Deutschland GmbH, is the Euro, for Glamsmile Asia Ltd., and its subsidiaries, the Hong Kong dollar and the Chinese Renminbi (“RMB”) for Mainland China. The assets and liabilities of companies whose functional currency is other that the U.S. dollar are included in the consolidation by translating the assets and liabilities at the exchange rates applicable at the end of the reporting period. The statements of income of such companies are translated at the average exchange rates during the applicable period. Translation gains or losses are accumulated as a separate component of stockholders’ equity.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) includes all changes in equity except those resulting from investments by owners and distributions to owners, including accumulated foreign currency translation, and unrealized gains or losses on ‘Available For Sale (AFS)’ securities.
Stock Based Compensation	Stock Based Compensation The Company had a stock-based compensation plan which is described more fully in Note 12. The Company measures the compensation cost of stock options and other stock-based awards to employees and directors at fair value at the grant date and recognizes compensation expense over the requisite service period for awards expected to vest. Except for transactions with employees and directors, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Additionally, the Company has determined that the dates used to value the transaction are either: (1) The date at which a commitment for performance by the counter party to earn the equity instruments is established; or (2) The date at which the counter party’s performance is complete.
Risk Management	Risk Management The Company’s credit risk is primarily attributable to its accounts receivable. The amounts presented in the accompanying consolidated balance sheets are net of allowances for doubtful accounts, estimated by the Company’s management based on prior experience and the current economic environment. The Company is exposed to credit-related losses in the event of non-payment by customers. Credit exposure is minimized by dealing with only credit worthy counterparties. Accounts receivable for the Company’s five primary customers totaled $53,647 or 11.09% at March 31, 2020 (March 31, 2019 - $92,409 or 23.59%). The credit risk on cash and cash equivalents is limited because the Company limits its exposure to credit loss by placing its cash and cash equivalents with major financial institutions. The Company has not experienced any material losses in such accounts. The Company is exposed to foreign exchange and interest rate risk to the extent that market value rate fluctuations materially differ from financial assets and liabilities, subject to fixed long-term rates. In order to manage its exposure to foreign exchange risks, the Company is closely monitoring the fluctuations in the foreign currency exchange rates and the impact on the value of cash and cash equivalents, accounts receivable, and accounts payable and accrued liabilities. The Company has not hedged its exposure to currency fluctuations.
Equity Method Investment	Equity Method Investment The Company accounts for investments using the equity method of accounting if the investment provides the Company the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company’s ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is recorded at cost in the consolidated balance sheets under other assets and adjusted for dividends received and the Company’s share of the investee’s earnings or losses together with other-than-temporary impairments which are recorded through interest and other loss, net in the consolidated statements of income and comprehensive income.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations. Adopted Accounting Pronouncements In February 2016, the FASB established ASU Topic 842 – Leases, by issuing ASU Topic No. 2016-02 (“Topic 842”), which requires lessees to recognize lease on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU Topic 2018-11 – Targeted Improvements. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and a lease liability for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted Topic 842 in the first quarter of 2019 utilizing the modified retrospective transition method and a cumulative effect adjustment at the beginning of the first quarter of 2019. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date, and (3) initial direct costs for any existing leases as of the adoption date. The Company did not elect to apply the hindsight practical expedient when determining lease term and assessing impairment of the right-to-use assets. The adoption of Topic 842 resulted in the recognition of right-of use assets of approximately $180,926 and lease liabilities for operating leases of approximately $180,926 and no cumulative effect adjustment on retained earnings on its unaudited Consolidated Balance Sheets or material impact to its unaudited Consolidated Statements of Operations and Comprehensive Loss in the period of adoption. Right-of-use assets are included in Prepaid and other assets, and lease liabilities are included in Accrued liabilities in the consolidated balance sheet. See Note 14 — Leases, for additional information.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of product warranty liability	A tabular reconciliation of the Company’s aggregate product warranty liability for the reporting period is as follows: Year ended Year ended March 31, 2020 March 31, 2019 Product warranty liability: Opening balance $ 5,619 $ 6,164 Accruals for product warranties issued in the period — — Adjustments to liabilities for pre-existing warranties (123) (545) Ending liability $ 5,496 $ 5,619

LONG-TERM INVESTMENTS (Tables)

LONG-TERM INVESTMENTS (Tables)	12 Months Ended
	Mar. 31, 2020
Long Term Investments [Line Items]
Schedule of conjunction with the transaction and resulting deconsolidation of company recorded a gain	In conjunction with the transaction and resulting deconsolidation of Glamsmile Dental, the Company recorded a gain of $1,470,776, calculated as follows: Consideration received $ 2,000,000 Fair value of 29.4% interest 2,055,884 Carrying value of non-controlling interest 1,117,938 Less: carrying value of former subsidiary’s net assets (2,002,329) Goodwill (699,635) Investment China & Hong Kong (1,082) Rescission agreement Excelsior (1,000,000) $ 1,470,776
Schedule of represent the summary financial information derived from its financial statements and prepared under US GAAP	The following tables represent the summary financial information of GlamSmile Asia as derived from its financial statements and prepared under US GAAP: Operating data: March 31, 2020 March 31, 2019 Revenues $ 4,026,904 $ 4,644,421 Gross profit 2,510,269 3,952,082 Income (loss) from operations (630,811) 380,539 Net income (loss) $ (725,675) $ 286,752
Metrics In Balance NV [Member]
Long Term Investments [Line Items]
Schedule of represent the summary financial information derived from its financial statements and prepared under US GAAP	The following tables represent the summary financial information of MIB as derived from its financial statements and prepared under US GAAP: Operating data: March 31, 2020 March 31, 2019 Revenues $ 58,441 $ 12,307 Gross profit 57,951 10,544 Income (loss) from operations (96,846) (322,463) Net income (loss) $ (82,071) $ (327,793)

ACCOUNTS RECEIVABLE AND ALLOW_2

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (Tables)	12 Months Ended
	Mar. 31, 2020
ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS
Schedule of accounts receivable	The Company’s accounts receivable at year end were as follows: March 31, 2020 March 31, 2019 Accounts receivable, gross $ 483,787 $ 391,811 Less: allowance for doubtful accounts (154,447) (157,903) Accounts receivable, net $ 329,340 $ 233,908

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Mar. 31, 2020
INVENTORIES
Schedule of inventories	Inventories at year end are stated at the lower of cost (first-in, first-out) or net realizable value and consisted of the following: March 31, 2020 March 31, 2019 Raw materials $ 7,483 $ 9,151 Components 91,808 121,941 Finished goods 564,654 577,303 663,945 708,395 Less: reserve for obsolescence (573,104) (597,433) Net inventory $ 90,841 $ 110,962

PREPAID EXPENSES (Tables)

PREPAID EXPENSES (Tables)	12 Months Ended
	Mar. 31, 2020
PREPAID EXPENSES
Schedule of prepaid expenses	Prepaid expenses are summarized as follows: March 31, 2020 March 31, 2019 Prepaid materials and components $ 51,050 $ 217,172 Prepaid trade show expense — 4,933 VAT payments in excess of VAT receipts 3,947 7,355 Other 4,418 15,064 Right-of-use assets 86,834 — $ 146,249 $ 244,524

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Mar. 31, 2020
PROPERTY AND EQUIPMENT
Schedule of property and equipment	Property and equipment are summarized as follows: March 31, 2020 March 31, 2019 Furniture and Fixtures $ 480,252 $ 478,406 Machinery and Equipment 1,917,825 2,154,822 2,398,077 2,633,228 Accumulated depreciation (2,330,985) (2,507,495) Property & equipment, net $ 67,092 $ 125,733

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Mar. 31, 2020
ACCRUED LIABILITIES
Schedule of accrued liabilities	Accrued liabilities are summarized as follows: March 31, 2020 March 31, 2019 Accrued employee benefit taxes and payroll $ 102,207 $ 176,858 Accrued travel 5,496 5,619 Accrued audit and tax preparation fees 17,395 23,255 Reserve for warranty costs 5,496 5,619 Accrued commission 15,000 — Accrued consulting fees 196,633 179,669 Tax reserve 5,630 753 VAT to be paid 7,997 7,462 Other accrued expenses + lease liability 130,909 51,112 $ 486,763 $ 450,347

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2020
INCOME TAXES
Schedule of domestic and foreign components of income (loss) before income taxes	The domestic and foreign (“Belgium”, “German”, “Italian”, Hong Kong and China) components of income (loss) before income taxes and minority interest were comprised of the following: March 31, 2020 March 31, 2019 Domestic $ (354,913) $ (655,273) Foreign (497,025) 2,775,270 $ (851,938) $ 2,119,997
Schedule of domestic and foreign components of deferred income taxes	The Company’s domestic and foreign components of deferred income taxes are as follows: March 31, 2020 March 31, 2019 Domestic — Net operating loss carryforward $ 8,680,733 $ 7,984,906 Foreign — Net operating loss carryforward (682,511) (831,619) Total 7,998,222 7,153,287 Valuation allowance (7,998,222) (7,153,287) Net deferred tax assets $ — $ —
Schedule of difference between the income tax (benefit) and the amounts computed by applying the statutory income tax rates to the income (loss)	The principal reasons for the difference between the income tax (benefit) and the amounts computed by applying the statutory income tax rates to the income (loss) for the year ended March 31, 2020 and March 31, 2019 are as follows: March 31, 2020 March 31, 2019 Domestic Pre tax income (loss) $ (354,913) $ (655,273) Statutory tax rate 27 % 27 % Tax benefit based upon statutory rate (95,827) (176,924) Valuation allowance 95,827 176,924 Net domestic income tax (benefit) — — Foreign Pre tax income (loss) (497,025) 2,775,270 Statutory tax rate 30 % 30 % Tax expense (benefit) based upon statutory rate (149,108) 832,581 Permanent differences 149,108 (832,581) — — Net foreign income tax expense (recovery) 2,329 874 Total Income tax expense (recovery) $ 2,329 $ 874

EQUITY COMPENSATION PLANS (Tabl

EQUITY COMPENSATION PLANS (Tables)	12 Months Ended
	Mar. 31, 2020
EQUITY COMPENSATION PLANS
Schedule of compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance	The following table provides aggregate information as of March 31, 2020 and March 31, 2019 with respect to all compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance. 2004 Plan 2007 Plan Weighted Weighted Average Average Outstanding Exercise Outstanding Exercise Options Price Options Price Options outstanding and exercisable March 31, 2018 357,500 0.50 430,000 1.21 Options expired (357,500) (430,000) Options outstanding and exercisable at March 31, 2020 and March 31, 2019 — —
Schedule of equity compensation plans approved and not approved by shareholders	A summary of the Company’s equity compensation plans approved and not approved by shareholders is as follows: Number of securities remaining available for future Number of issuance securities to under be equity issued upon Weighted-average compensation exercise of exercise price of plans outstanding outstanding (excluding options, options securities warrants warrants and reflected Plan Category and rights rights in column (a)) Equity Compensation Plans approved by security holders — $ — 1,962,500

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Mar. 31, 2020
LEASES
Schedule of information related to the right-of-use assets and related liabilities	Information related to the Company’s right-of-use assets and related liabilities were as follows: March 31, 2020 Cash paid for operating lease liabilities $ 103,370 Right-of-use assets obtained in exchange for new operating lease obligations Weighted-average remaining lease term, real estate 0.75 years Weighted-average remaining lease term, all other leased equipment 1.84 years Weighted-average discount rate 12 %
Schedule of maturities of lease liabilities	Maturities of lease liabilities as of March 31, 2020, were as follows: Due in 12-month period ended March 31: 2021 $ 85,550 Thereafter 5,569 $ 91,119 Less imputed interest (4,285) Total lease liabilities $ 86,834 Current operating lease liabilities $ 81,379 Non-current lease liabilities 5,455 Total lease liabilities $ 86,834

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Mar. 31, 2020
FINANCIAL INSTRUMENTS
Schedule of carrying values and fair values of our financial instruments	The carrying values and fair values of our financial instruments are as follows: March 31, 2020 March 31, 2019 Carrying Fair Carrying Fair Level value Value value value Cash 1 114,634 $ 114,634 $ 66,539 $ 66,539 Accounts receivable 2 329,340 $ 329,340 $ 233,908 $ 233,908 Long Term investment and advance - GlamSmile Dental Technology Asia 3 2,150,724 $ 2,150,724 $ 2,306,817 $ 2,306,817 Long term investments and advances Condor 1 1,159,561 $ 1,159,561 $ 1,335,680 $ 1,335,680 Long term investment in Metrics in Balance 1 3,450,598 $ 3,450,598 3,472,011 3,472,011 Deferred revenue 2 100,571 $ 100,571 $ 63,852 $ 63,852 Accounts payable 2 2,294,884 $ 2,294,884 $ 1,919,095 $ 1,919,095 Accrued liabilities 2 486,763 $ 486,763 $ 450,347 $ 450,347
Schedule of reconciliation of the beginning and ending balances of the item measured at fair value on a recurring basis in the table above that used significant unobservable inputs (Level 2)	The following table provides a reconciliation of the beginning and ending balances of the item measured at fair value on a recurring basis in the table above that used significant unobservable inputs (Level 2): Year ended March 31, Year ended March 31, 2020 2019 Long term investments and advances: Beginning balance $ 2,306,817 $ 2,245,137 Gains (losses) included in net loss (156,093) 61,680 Transfers in (out of level 3) — — Ending balance $ 2,150,724 $ 2,306,817

DESCRIPTION OF THE COMPANY AN_2

DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION
Working Capital Deficit	$ 2,201,154
Accumulated deficit	$ (18,575,388)	$ (17,717,166)

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product warranty liability (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Product warranty liability:
Opening balance	$ 5,619	$ 6,164
Accruals for product warranties issued in the period	0	0
Adjustments to liabilities for pre-existing warranties	(123)	(545)
Ending liability	$ 5,496	$ 5,619

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional information (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Apr. 01, 2019	Mar. 31, 2014	Jan. 01, 2010
Accounting Policies [Line Items]
Impairment Charges	$ 0
Inventory Valuation Reserves	573,104	$ 597,433
Provision For Warranty Costs	5,496	5,619
Advertising Expense	$ 38,155	$ 138,747
Common Stock, Shares, Issued	19,995,969	19,995,969
Common Stock, Shares, Outstanding	19,995,969	19,995,969
Accounts Receivable, Net, Current	$ 329,340	$ 233,908
Right-of-use assets	86,834	0
Lease liabilities	86,834
Retained earnings	$ (18,575,388)	(17,717,166)
Minimum [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	20.00%
Maximum [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	50.00%
Customer Category Five [Member]
Accounting Policies [Line Items]
Accounts Receivable, Net, Current	$ 53,647	$ 92,409
Concentration Risk, Percentage	11.09%	23.59%
Equity Option [Member]
Accounting Policies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	0	0
Tools, Dies and Molds [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Machinery and Equipment [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	4 years
ASU 2016-02
Accounting Policies [Line Items]
Right-of-use assets			$ 170,898
Lease liabilities			$ 170,898
ASU 2016-02 | Restatement Adjustment [Member]
Accounting Policies [Line Items]
Right-of-use assets		$ 180,926
Lease liabilities		180,926
Retained earnings		$ 0
GlamSmile Deutschland GmbH [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	51.00%
GlamSmile Asia [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	100.00%			21.51%
Retained earnings					$ 73,302
Beijing Glamsmile Trading Co Ltd [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	80.00%
Beijing Glamsmile Dental Clinic Co Ltd [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	98.00%
Shanghai Glamsmile Dental Clinic Co Ltd [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	100.00%
Whenzhou Glamsmile Dental Clinic Ltd [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	50.00%
Glamsmile Dental Technology Ltd [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	21.51%			21.51%
Accounts Receivable, Net, Current				$ 1,150,000
Glam Smile Rome [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	80.00%
Biotech Dental Benelux N.V [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	50.00%
Guangzhou Dental Clinic Co., Ltd. [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage	100.00%

LONG-TERM INVESTMENTS (Details)

LONG-TERM INVESTMENTS (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Carrying value of non-controlling interest	$ 74,678	$ 70,723
Glamsmile Dental Technology Ltd [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received		2,000,000
Fair value of 29.4% interest		2,055,884
Carrying value of non-controlling interest		1,117,938
Less: carrying value of former subsidiary's net assets		(2,002,329)
Goodwill		(699,635)
Investment China & Hong Kong		(1,082)
Rescission agreement Excelsior (Note 11)		(1,000,000)
Disposal Group Including Discontinued Operation Liability Assets Net		$ 1,470,776

LONG-TERM INVESTMENTS - Summary

LONG-TERM INVESTMENTS - Summary of represent the summary financial information derived from its financial statements and prepared under US GAAP (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating data:
Revenues	$ 1,064,419	$ 1,603,741
Gross profit	742,171	1,117,246
Income (loss) from operations	(479,607)	(717,347)
Net income	(858,222)	2,128,796
GlamSmile Asia [Member]
Operating data:
Revenues	4,026,904	4,644,421
Gross profit	2,510,269	3,952,082
Income (loss) from operations	(630,811)	380,539
Net income	(725,675)	286,752
MIB [Member]
Operating data:
Revenues	58,441	12,307
Gross profit	57,951	10,544
Income (loss) from operations	(96,846)	(322,463)
Net income	$ (82,071)	$ (327,793)

LONG-TERM INVESTMENTS - Additio

LONG-TERM INVESTMENTS - Additional information (Details)	Mar. 29, 2019EUR (€)shares	Nov. 22, 2018shares	Apr. 16, 2018EUR (€)	Apr. 16, 2018USD ($)	Mar. 31, 2014USD ($)	Jan. 30, 2014USD ($)shares	Jan. 28, 2012USD ($)shares	Mar. 31, 2020USD ($)shares	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2012USD ($)	Mar. 31, 2011EUR (€)shares	Mar. 31, 2011USD ($)shares	Mar. 31, 2010USD ($)	Dec. 31, 2019	Mar. 31, 2019€ / shares	Mar. 31, 2019USD ($)multiple$ / sharesshares	Mar. 29, 2019USD ($)shares	Mar. 31, 2013	Feb. 10, 2012	Jan. 20, 2012USD ($)shares	Jun. 27, 2011USD ($)	Jan. 01, 2010USD ($)
Long Term Investments [Line Items]
Income (Loss) from Equity Method Investments								$ (353,625)	$ 2,851,529
Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee									3,007,301
Accumulated deficit								$ (18,575,388)									$ (17,717,166)
Preferred Stock, shares outstanding | shares								0									0
Preferred stock, shares issued | shares								0									0
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)								$ 0									$ 0
Shares Acquired From Investment | shares																	70,334
Fair Market Value Of Investment																	$ 787,339
Fair Market Price Per Share | (per share)																€ 8.70	$ 11.19
Accounts Receivable, Net, Current								329,340									$ 233,908
Loss On Equity Method Investment																	$ 174,479
Weighted Average Cost Of Capital Percentage																	23.00%
Net Income (Loss) Attributable to Parent								$ (858,222)	2,128,796
Minimum [Member]
Long Term Investments [Line Items]
Equity Method Investment, Ownership Percentage								20.00%
Saas Multiples | multiple																	5.1
Maximum [Member]
Long Term Investments [Line Items]
Equity Method Investment, Ownership Percentage								50.00%
Saas Multiples | multiple																	18.5
Smilewise Corporate BVBAMember [Member]
Long Term Investments [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%																	100.00%
Percentage Of Investments Acquired From Issued And Outstanding Shares			60.00%	60.00%
Payments to Acquire Investments			€ 2,226	$ 2,592
Metrics In Balance NV [Member]
Long Term Investments [Line Items]
Equity Method Investment, Realized Gain (Loss) on Disposal								$ 21,413	2,832,822
Income (Loss) from Equity Method Investments								$ (21,413)	2,832,822
Business Acquisition, Percentage of Voting Interests Acquired	60.00%																	60.00%
Percentage Of Investments Acquired From Issued And Outstanding Shares		3.08%
Shares Acquired From Investments | shares		63,112
Condor Technologies NV [Member]
Long Term Investments [Line Items]
Fair Value, Option, Changes in Fair Value, Gain (Loss)									(176,119)
Fair Value Per Share | (per share)																€ 1,500	$ 16.49
Condor Technologies NV [Member] | Accounting Standards Update 2016-01 [Member]
Long Term Investments [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption										$ 178,361
GlamSmile Asia [Member]
Long Term Investments [Line Items]
Equity Method Investment, Ownership Percentage					21.51%			100.00%
Business Acquisition, Percentage of Voting Interests Acquired															50.98%								50.98%
Payments to Acquire Businesses, Gross												€ 325,000	$ 466,725
Stock Issued During Period, Value, New Issues														$ 97,500
Stock Issued During Period, Shares, New Issues | shares												250,000	250,000
Accumulated deficit																							$ 73,302
Payments for Advance to Affiliate													$ 101,245	196,599
Due to Related Parties, Noncurrent														$ 196,599								$ 95,354
Deconsolidation, Gain (Loss), Amount									1,470,776
GlamSmile Asia [Member] | Options Held [Member]
Long Term Investments [Line Items]
Stock Issued During Period, Shares, New Issues | shares												100,000	100,000
GlamSmile Asia [Member] | Opened Store Option [Member]
Long Term Investments [Line Items]
Stock Issued During Period, Shares, New Issues | shares												100,000	100,000
GlamSmile Asia [Member] | Additional Store Opened Option [Member]
Long Term Investments [Line Items]
Stock Issued During Period, Shares, New Issues | shares												100,000	100,000
Glamsmile Dental Technology Ltd [Member]
Long Term Investments [Line Items]
Equity Method Investment, Ownership Percentage					21.51%			21.51%
Equity Method Investment, Realized Gain (Loss) on Disposal						$ 1,582,597		$ (156,093)	61,680
Unrealized Gain (Loss) on Investments									$ (156,093)	$ 61,680
Equity Method Investment, Net Sales Proceeds					$ 1,850,000
Discontinued Operation, Amounts of Material Contingent Liabilities Remaining							$ 1,500,000
Stock Transferred During Period, Shares, Contingent Consideration | shares							500,000
Equity Method Investment Sold Number Of Shares | shares						2,500,000
Equity Method Investment, Amount Sold						$ 3,000,000
Accounts Receivable, Net, Current					$ 1,150,000
Glamsmile Dental Technology Ltd [Member] | Investor [Member]
Long Term Investments [Line Items]
Equity Method Investment, Ownership Percentage																				31.40%
Glamsmile Dental Technology Ltd [Member] | Gallant [Member]
Long Term Investments [Line Items]
Equity Method Investment, Ownership Percentage																				39.20%
Glamsmile Dental Technology Ltd [Member] | De Vreese [Member]
Long Term Investments [Line Items]
Equity Method Investment, Ownership Percentage																				29.40%
Glamsmile Dental Technology Ltd [Member] | Series A Preferred Stock [Member]
Long Term Investments [Line Items]
Preferred Stock, shares outstanding | shares							5,000,000
Preferred Stock, Value, Outstanding							$ 5,000,000
Glamsmile Dental Technology Ltd [Member] | Preference A-1 Shares [Member]
Long Term Investments [Line Items]
Preferred Stock, shares outstanding | shares							2,857,143
Preferred stock, shares issued | shares																					2,857,143
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)																					$ 250,000
Preferred Stock, Value, Outstanding							$ 2,000,000
Medical Franchises And Investments [Member]
Long Term Investments [Line Items]
Percentage Of Investments Acquired From Issued And Outstanding Shares																			6.12%
Payments to Acquire Investments											$ 314,778
Metrics In Balance NV [Member]
Long Term Investments [Line Items]
Percentage Of Investments Acquired From Issued And Outstanding Shares		26.09%
Cash Payments Converted	€ 110,271																	$ 123,912
Cash Payments Converted Shares | shares	1,082,190																	1,082,190
Shares Acquired From Investments | shares	1,145,302

CONCENTRATION OF RISK (Details)

CONCENTRATION OF RISK (Details)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Customer Category Five [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	11.09%	23.59%
Sales Revenue, Net [Member] | Customer Category Five [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	26.30%	64.48%
Sales Revenue, Net [Member] | Customer Category One [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	9.07%	22.90%
Accounts Receivable [Member] | Customer Category Five [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	11.09%	23.59%
Accounts Receivable [Member] | Customer Category One [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	2.89%	6.93%
Accounts Payable [Member] | Customer Category Five [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	40.15%	48.86%
Accounts Payable [Member] | Customer Category One [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	36.29%	42.18%

ACCOUNTS RECEIVABLE AND ALLOW_3

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS
Accounts receivable, gross	$ 483,787	$ 391,811
Less: allowance for doubtful accounts	(154,447)	(157,903)
Accounts receivable, net	$ 329,340	$ 233,908

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
INVENTORIES
Raw materials	$ 7,483	$ 9,151
Components	91,808	121,941
Finished goods	564,654	577,303
Inventory, Gross	663,945	708,395
Less: reserve for obsolescence	(573,104)	(597,433)
Net inventory	$ 90,841	$ 110,962

PREPAID EXPENSES (Details)

PREPAID EXPENSES (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
PREPAID EXPENSES
Prepaid materials and components	$ 51,050	$ 217,172
Prepaid trade show expense	0	4,933
VAT payments in excess of VAT receipts	3,947	7,355
Other	4,418	15,064
Right-of-use assets	86,834	0
Prepaid Expenses	$ 146,249	$ 244,524

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
PROPERTY AND EQUIPMENT
Furniture and Fixtures	$ 480,252	$ 478,406
Machinery and Equipment	1,917,825	2,154,822
Property, Plant and Equipment, Gross	2,398,077	2,633,228
Accumulated depreciation	(2,330,985)	(2,507,495)
Property & equipment, net	$ 67,092	$ 125,733

DUE TO RELATED PARTIES AND RE_2

DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS
Related Party Transaction, Expenses from Transactions with Related Party	$ 192,758	$ 221,130

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
ACCRUED LIABILITIES
Accrued employee benefit taxes and payroll	$ 102,207	$ 176,858
Accrued travel	5,496	5,619
Accrued audit and tax preparation fees	17,395	23,255
Reserve for warranty costs	5,496	5,619
Accrued commission	15,000
Accrued consulting fees	196,633	179,669
Tax reserve	5,630	753
VAT to be paid	7,997	7,462
Other accrued expenses + lease liability	130,909	51,112
Accrued Liabilities, Current	$ 486,763	$ 450,347

INCOME TAXES - Income (loss) be

INCOME TAXES - Income (loss) before income taxes (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
INCOME TAXES
Domestic	$ (354,913)	$ (655,273)
Foreign	(497,025)	2,775,270
Total	$ (851,938)	$ 2,119,997

INCOME TAXES - Deferred income

INCOME TAXES - Deferred income taxes (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
INCOME TAXES
Domestic - Net operating loss carryforward	$ 8,680,733	$ 7,984,906
Foreign - Net operating loss carryforward	(682,511)	(831,619)
Total	7,998,222	7,153,287
Valuation allowance	(7,998,222)	(7,153,287)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES- Reconciliation on

INCOME TAXES- Reconciliation on income tax rate (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Pre tax income (loss)	$ (851,938)	$ 2,119,997
Total Income tax expense (recovery)	2,329	874
Domestic [Member]
Pre tax income (loss)	$ (354,913)	$ (655,273)
Statutory tax rate	27.00%	27.00%
Tax expense (benefit) based upon statutory rate	$ (95,827)	$ (176,924)
Valuation allowance	95,827	176,924
Total Income tax expense (recovery)	0	0
Foreign [Member]
Pre tax income (loss)	$ (497,025)	$ 2,775,270
Statutory tax rate	30.00%	30.00%
Tax expense (benefit) based upon statutory rate	$ (149,108)	$ 832,581
Permanent differences	149,108	(832,581)
Total Income tax expense (recovery)	0	0
Net foreign income tax expense (recovery)	$ 2,329	$ 874

EQUITY COMPENSATION PLANS - Equ

EQUITY COMPENSATION PLANS - Equity securities are authorized for issuance (Details) - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Plan 2004 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding and exercisable	357,500
Weighted Average Exercise Price, Options outstanding		$ 0.50
Options expired unexercised	(357,500)
Options outstanding and exercisable	0
Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding and exercisable	430,000
Weighted Average Exercise Price, Options outstanding		$ 1.21
Options expired unexercised	(430,000)
Options outstanding and exercisable	0

EQUITY COMPENSATION PLANS - E_2

EQUITY COMPENSATION PLANS - Equity compensation plans approved and not approved by shareholders (Details) - Equity Compensation Plan Approved By Security Holders [Member]	Mar. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities to be issued upon exercise of outstanding options, warrants and rights	0
Weighted-average exercise price of outstanding options, warrants and rights | $ / shares	$ 0
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))	1,962,500

EQUITY COMPENSATION PLANS - Add

EQUITY COMPENSATION PLANS - Additional information (Details) - shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0
Plan 2004 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options		800,000
Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options		1,000,000

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
SEGMENT INFORMATION
Disclosure on Geographic Areas, Description of Revenue from External Customers	Our operations are primarily in Europe and Asia and 100% of our sales for the fiscal year ended March 31, 2020 and 100% of our sales for the fiscal year ended March 31, 2019 were generated from customers outside of the United States.
Segment operations ,Percentage	100.00%	100.00%

LEASES - Right-of-use assets an

LEASES - Right-of-use assets and related liabilities (Details)	12 Months Ended
	Mar. 31, 2020USD ($)
LEASES
Cash paid for operating lease liabilities	$ 103,370
Weighted-average remaining lease term, real estate	9 months
Weighted-average remaining lease term, all other leased equipment	1 year 10 months 2 days
Weighted-average discount rate	12.00%

LEASES - Maturities of lease li

LEASES - Maturities of lease liabilities (Details)	Mar. 31, 2020USD ($)
LEASES
2021	$ 85,550
Thereafter	5,569
Total	91,119
Less imputed interest	(4,285)
Total lease liabilities	$ 86,834
Operating Lease, Liability, Statement of Financial Position [Extensible List]	Liabilities
Current operating lease liabilities	$ 81,379
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued Liabilities, Current
Non-current lease liabilities	$ 5,455
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term Debt

LEASES - Additional information

LEASES - Additional information (Details) - USD ($)	Apr. 01, 2019	Mar. 31, 2019	Mar. 31, 2020
LEASES
Right-of-use assets		$ 0	$ 86,834
Lease liabilities			$ 86,834
Cumulative-effect adjustment to retained earnings		$ 0
Weighted-average discount rate			12.00%
ASU 2016-02
LEASES
Right-of-use assets	$ 170,898
Lease liabilities	170,898
Cumulative-effect adjustment to retained earnings	$ 0

FINANCIAL INSTRUMENTS - Carryin

FINANCIAL INSTRUMENTS - Carrying values and fair values (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash, Carrying Value	$ 114,634	$ 66,539
Accounts receivable, Carrying Value	329,340	233,908
Long Term investment and advance - GlamSmile Dental Technology Asia, Carrying Value	1,159,561	1,335,680
Deferred revenue, Carrying Value	100,571	63,852
Accounts payable, Carrying Value	2,294,884	1,919,095
Accrued liabilities, Carrying Value	486,763	450,347
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash, Carrying Value	114,634	66,539
Cash, Fair Value	114,634	66,539
Long term investments and advances Condor, Carrying Value	1,159,561	1,335,680
Long term investments and advances Condor, Fair Value	1,159,561	1,335,680
Long term investment Metrics in Balance, Carrying Value	3,450,598	3,472,011
Long term investment Metrics in Balance, Fair Value	3,450,598	3,472,011
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Accounts receivable, Carrying Value	329,340	233,908
Accounts receivable, Fair Value	329,340	233,908
Deferred revenue, Carrying Value	100,571	63,852
Deferred revenue, Fair Value	100,571	63,852
Accounts payable, Carrying Value	2,294,884	1,919,095
Accounts payable, Fair Value	2,294,884	1,919,095
Accrued liabilities, Carrying Value	486,763	450,347
Accrued liabilities, Fair Value	486,763	450,347
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long Term investment and advance - GlamSmile Dental Technology Asia, Carrying Value	2,150,724	2,306,817
Long Term investment and advance - GlamSmile Dental Technology Asia, Fair Value	$ 2,150,724	$ 2,306,817

FINANCIAL INSTRUMENTS - Additio

FINANCIAL INSTRUMENTS - Additional information (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Long term investments and advances:
Beginning balance	$ 2,306,817	$ 2,245,137
Gains (losses) included in net loss	(156,093)	61,680
Transfers in (out of level 3)	0	0
Ending balance	$ 2,150,724	$ 2,306,817